相关实验视频
Updated: Jun 29, 2026
08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
7.1K
SITC的前景:利用患者丰富生物标志物加速早期IO药物开发
Leisha A Emens1, Christine Moussion2, Patrick Hwu3
1Kaiser Permanente, South Sacramento, California, USA emensle@icloud.com.
Journal for immunotherapy of cancer
|June 23, 2025
概括
基于生物标志物的丰富策略可以改善癌症免疫治疗药物开发. 这种方法减轻了与患者异质性相关的风险,加速了向患者提供创新的治疗方法.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 生物标志物发现发现
背景情况:
- 癌症免疫疗法 (IO) 提供了显著的患者益处,但由于药物开发失败而面临挑战.
- 患者的异质性,包括瘤特征和治疗史,增加了丢弃潜在有效IO药物的风险.
- 癌症免疫疗法协会 (SITC) 召集了利益相关者,以应对IO药物开发中的这些挑战.
研究的目的:
- 提出一个利用生物标志物的框架,在药物开发的早期,以加快提供创新的IO代理商.
- 为了减轻因患者异质性而丢弃临床活性IO药物的风险.
- 提高IO药物的后期临床试验的成功率.
主要方法:
- 开发一个框架,在早期临床试验中整合基于生物标志物的丰富策略.
- 丰富策略的演变,在晚期试验中,向精确的预测生物标志物发展.
- 从临床前数据,数字病理学,多态学和人工智能中整合机械学的见解.
- 通过自适应性和随机临床试验不断改进.
主要成果:
- 在早期IO试验中基于生物标志物进行丰富的建议框架.
- 通过识别具有更高临床益处概率的患者来降低晚期试验风险的策略.
- 扩大患者可用的创新IO药物组合的潜力.
结论:
- 在早期临床开发中基于生物标志物的丰富对于成功的IO药物开发至关重要.
- 该策略解决了患者异质性的问题,降低了试验失败的风险.
- 实施这一框架可以加快新型癌症免疫疗法的可用性.
相关概念视频
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...